Instruction for use: Immunal plus C

Dosage form: Solution for oral administration

ATX

L03AX Other immunostimulants

Pharmacological group:

Immunostimulating agent of vegetable origin [Other immunomodulators]

The nosological classification (ICD-10)

B99 Other infectious diseases: Infections (opportunistic); Infections on the background of immunodeficiency; Opportunistic infections

D84.9 Unspecified Immunodeficiency: Pneumonia in immunodeficient states; Autoimmune disease; Autoimmune diseases; Severe immunodeficiency; immune deficiency; Immunodeficiency; immunodeficiency diseases; Immunodeficiency states due to surgery; Immunotherapy for cancer; Immunomodulation; Infections in patients with weakened immune systems; Correction of immune deficiency; Correction of immunodeficiencies; Correction of a weakened immune system; Correction of a weakened immunity in immunodeficient states; Violation of immunity; Violation of the immune status; Immune System Disorders; Primary immunodeficiency; Maintaining immunity; Lowering the body's defenses; Lowering the immunity; Lowering the immunity of colds and infectious diseases; The decrease of the immune status; Lowered resistance to infections; Lowered resistance to infections and colds; Lowered resistance; Immunosuppression; Predisposition to colds; acquired immune deficiencies; Radiation immunodeficiency; The development of immunodeficiency; Immune dysfunction syndrome; immunodeficiency syndrome; primary immunodeficiency syndrome; Reducing the body's defenses; Immunosuppression; Reduced immune defense; Reducing local immunity; Reducing the total body resistance; The decrease in cell-mediated immunity; Reduced resistance to infections in children; Reducing the body's resistance; Reduced resistance; reduced immunity; Status immunodeficiency; Stimulation of the processes of nonspecific immunity; Heavy selective secondary immunodeficiency; immunity Oppression; Primary immunodeficiency

J06 Acute upper respiratory tract infections of multiple and unspecified locations: Frequent colds of viral diseases; Infections of ENT organs; Acute respiratory illness of influenza nature; Pain for colds; Acute catarrhal disease; Cold; Colds; Colds; Respiratory infection; Seasonal catarrhal disease; Seasonal colds; Pain in infectious and inflammatory diseases of the upper respiratory tract; Bacterial infections of the upper respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory disease of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract with difficult to separate sputum; Inflammatory respiratory disease; Secondary infections for colds; Difficult sputum separation in acute and chronic respiratory diseases; Upper respiratory tract infections; Infections of the upper respiratory tract; Respiratory tract infections; Respiratory and lung infections; Infectious-inflammatory diseases of the upper respiratory tract; Infectious-inflammatory diseases of the upper respiratory tract and ENT organs; Infectious-inflammatory diseases of the upper respiratory tract in adults and children; Infectious-inflammatory diseases of the upper respiratory tract; Infectious inflammation of the respiratory tract; Respiratory tract infection; Qatar upper respiratory tract; Catarrh of the upper respiratory tract; Catarrh of the upper respiratory tract; Catarrhal phenomena from the upper respiratory tract; Cough in diseases of the upper respiratory tract; Cough for colds; ARVI; ARI; ARI with phenomena of rhinitis; Acute respiratory infection; Acute infectious-inflammatory disease of the upper respiratory tract; Acute respiratory disease; Persecution in the throat or nose; Respiratory and viral infections; Respiratory diseases; Respiratory infections; Recurrent respiratory tract infections; Secondary infections with influenza; Influenza states; Feverish conditions for influenza

Y40 Adverse reactions in the therapeutic use of systemic action antibiotics

Composition

Solution for oral administration 1 ml

active substance: Echinacea Purple Herb Juice Dried * 46.5 mg

Ascorbic acid ** 20 mg

Auxiliary substances: potassium sorbate - 2 mg; Disodium edetate - 0.5 mg; Orange flavoring - 1,5 mg; Maltitol (liquid) - 650 mg; Purified water - 486.1 mg; Sodium hydroxide 1.6 mg

* Echinacea of purple grass, the dried juice is obtained from the freshly picked Echinacea purpurea grass - Echinacea purpurea L. (Moench), the average ratio of Echinacea juice: dried Echinacea juice is 18-25: 1; Ratio freshly picked grass: dried juice - 30-60: 1

** ascorbic acid is added with an excess of 10% in order to stabilize

Pharmachologic effect

Mode of action - Immunosuppressive.

Dosing and Administration

Inside, regardless of food intake.

Adults and children over 12 years - 2-3 ml 3 times a day.

Children aged 4 to 12 years - 1-2 ml 3 times a day; From 1 year to 4 years - 1 ml 3 times a day.

To achieve a therapeutic effect, ImmunalŪ plus C should be taken within 7-10 days. Repeated courses are possible after a 14-day break.

Release form

Solution for oral administration. 50 ml in a bottle of yellow glass, sealed with a plastic screw cap, with the control of the first autopsy. The bottle together with a graduated metering syringe made of PE with a protective cap or without a cap is placed in a cardboard box.

Manufacturer

Sandoz d.d., Verovshkova 57, 1000, Ljubljana, Slovenia.

Produced: Lek dd, Verovshkova 57, 1526, Ljubljana, Slovenia.

Claims of consumers to send to ZAO Sandoz

Conditions of supply of pharmacies

Without recipe.

Storage conditions of the drug Immunal plus C

In the dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life of the drug Immunal plus C

2 years.

Do not use after the expiry date printed on the package.